ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Heteroresistance in vancomycin-variable Enterococcus faecium ST80 isolate.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the gradual genetic changes occurred in heteroresistant vancomycin-variable (VVE) Enterococcus faecium ST80 isolate - belonging to the vanA ST80 nosocomial clone although recovered from marine environment - contributing to its reversion to a resistant phenotype after exposure to increasing concentrations of vancomycin.
methodsWGS of the parental strain and three revertants obtained by exposure to vancomycin was performed. vanA copy number and difference in vanA expression between VVE and revertants were evaluated by RT-qPCR. Heteroresistance was demonstrated by vancomycin E-test and population analysis profiling.
resultsThe E. faecium JSEG15 isolate, susceptible to vancomycin although carrying a Tn1546-like transposon on 36-kb plasmid, gave rise to three different resistant mutants following gradual passages on increasing vancomycin concentrations. Revertants showed increased vancomycin MICs, with the highest resistance in JSEG15-rev3 (MIC = 128 mg/L). All revertants presented a deleted Tn1546-like on a 34-kb plasmid and JSEG15-rev2 and JSEG15-rev3 also showed an additional chromosomal copy of the vanRS and vanHAX clusters, and higher vanA gene copies and expression. A mutation in the chromosomal D-Ala-D-Ala ligase gene was identified in JSEG15-rev3 which also transferred the vanA carrying plasmid by in vitro conjugation. The parental strain and all revertants exhibited heteroresistance, with higher frequency of resistant subpopulations in the revertants.
conclusionThese findings emphasize the dynamic genetical changes enabling VVE to regain full resistance, underscoring the need for vigilant treatment strategies to address enterococcal infections and for monitoring the spread of clinically relevant strains in the environment for public health protection.
Indexed as
Identifiers
41606382What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.